@article{oai:nagasaki-u.repo.nii.ac.jp:00004145,
 author = {Kaneko, Kenichi and Takahashi, Haruo},
 issue = {6},
 journal = {ORL},
 month = {Feb},
 note = {Background: Bisphosphonates are widely used for the treatment of osteoporosis and other bone-degrading disorders; however, bisphosphonate therapy is an important risk factor for osteonecrosis of the jaws. Methods: We report a rare case of bisphosphonate-related osteonecrosis of the palatal torus. Results: The patient was a 72-year-old woman with osteoporosis who had received 35 mg alendronate sodium hydrate once every week for 6 years. She had a 2-month history of oral pain because of intractable mucositis and ulceration of the palatal torus, with no history of malignant disease, radiation therapy, chemotherapy, steroid use, or recent dentoalveolar surgery. A CT scan showed a bony prominence at the midportion of the hard palate with erosion of its cortex. Her condition was diagnosed as stage 2 bisphosphonate-related osteonecrosis of the jaw caused by trauma, and she was advised to discontinue alendronate. She was prescribed oral antibiotics for 5 days and an oral antibacterial rinse. The mucositis with ulceration healed in approximately 10 weeks, but left a small scar. Conclusions: Although osteonecrosis of the palatal torus associated with bisphosphonate use is a rare condition, otolaryngologists should consider this condition in the differential diagnosis of intractable ulceration of the hard palate., ORL, 76(6), pp.353-356; 2015},
 pages = {353--356},
 title = {Bisphosphonate-Related Osteonecrosis of the Palatal Torus},
 volume = {76},
 year = {2015}
}